[1]
G. Fuca, E. Verzoni, A. Mennitto, M. Prisciandaro, R. Ratta, and G. Procopio, “Real-world safety profile of abiraterone acetate in patients with castration-resistant prostate cancer and cardiovascular comorbidities: a retrospective, single center study:  ”, CBN, vol. 5, no. 3, pp. 20–24, Dec. 2017.